AR125353A1 - Agentes radioterapéuticos dirigidos al receptor de folato y su uso - Google Patents
Agentes radioterapéuticos dirigidos al receptor de folato y su usoInfo
- Publication number
- AR125353A1 AR125353A1 ARP220100955A ARP220100955A AR125353A1 AR 125353 A1 AR125353 A1 AR 125353A1 AR P220100955 A ARP220100955 A AR P220100955A AR P220100955 A ARP220100955 A AR P220100955A AR 125353 A1 AR125353 A1 AR 125353A1
- Authority
- AR
- Argentina
- Prior art keywords
- folate receptor
- subject
- effective amount
- compound
- radioelement
- Prior art date
Links
- 102000006815 folate receptor Human genes 0.000 title abstract 4
- 108020005243 folate receptor Proteins 0.000 title abstract 4
- 230000003439 radiotherapeutic effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000003384 imaging method Methods 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación se refiere a compuestos radioterapéuticos dirigidos al receptor de folato y su uso. La presente divulgación se refiere a conjugados radiomarcados para la obtención de imágenes dirigidos al receptor de folato y su uso. La presente divulgación además se refiere a composiciones farmacéuticas de los compuestos y conjugados que se describen en el presente documento, métodos de realizarlos y métodos para utilizarlos. Un compuesto de fórmula (1), BL-(Lˣ)ₖ-A (1) o una sal farmacéuticamente aceptable del mismo, en donde BL es un ligando de unión al receptor del folato, A es un grupo quelante Ch que puede comprender un metal, un radioelemento, Si-¹⁸F, B-¹⁸F o Al-¹⁸F, o A es un grupo prostético radiomarcado PG, k es 1, 2, 3, 4, 5, 6, 7, 8, 9 o 10, y cada Lˣ es independientemente AA, L¹, L² o L³, en donde cada AA es independientemente un residuo de aminoácidos, cada L¹ es independientemente de la fórmula (2); en donde todos los elementos de la fórmula (1) son como se definen en la reivindicación 1. Reivindicación 60: Un método para tratar una enfermedad proliferativa en un sujeto que lo necesita, que comprende administrarle al sujeto una cantidad terapéuticamente eficaz de un compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con una cualquiera de las reivindicaciones 1 a 55, o una cantidad terapéuticamente eficaz de una composición farmacéutica de la reivindicación 57, en donde el compuesto comprende un grupo quelante que quela un radioelemento. Reivindicación 69: Un método para obtener imágenes de las células que expresan FR en un sujeto, que comprende administrarle al sujeto una cantidad eficaz de un compuesto, o una sal farmacéuticamente aceptable del mismo, de acuerdo con una cualquiera de las reivindicaciones 1 a 56, o una cantidad eficaz de una composición farmacéutica de la reivindicación 57, en donde el compuesto comprende un metal, un radioelemento o un radiohalógeno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163175883P | 2021-04-16 | 2021-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125353A1 true AR125353A1 (es) | 2023-07-12 |
Family
ID=81384670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100955A AR125353A1 (es) | 2021-04-16 | 2022-04-13 | Agentes radioterapéuticos dirigidos al receptor de folato y su uso |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP4323017A1 (es) |
JP (1) | JP2024516797A (es) |
KR (1) | KR20230171964A (es) |
CN (1) | CN117083088A (es) |
AR (1) | AR125353A1 (es) |
AU (1) | AU2022257363A1 (es) |
BR (1) | BR112023021189A2 (es) |
CA (1) | CA3214074A1 (es) |
CL (1) | CL2023003063A1 (es) |
CO (1) | CO2023013494A2 (es) |
IL (1) | IL307499A (es) |
MX (1) | MX2023012114A (es) |
TW (1) | TW202304518A (es) |
WO (1) | WO2022219569A1 (es) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU634314B2 (en) | 1989-11-13 | 1993-02-18 | Green Cross Corporation, The | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
CA2090105A1 (en) | 1990-08-29 | 1992-03-01 | Jean-Paul Soulillou | Protein polyligands joined to a stable protein core |
US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
US9265746B2 (en) * | 2006-05-31 | 2016-02-23 | Merck & Cie | Method for cell-specific targeting |
RU2497825C1 (ru) * | 2012-07-03 | 2013-11-10 | Государственное Научное Учреждение "Институт Физики Имени Б.И. Степанова Национальной Академии Наук Беларуси" | Конъюгат фолиевой кислоты и способ его получения |
WO2014062697A2 (en) * | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
US9365599B2 (en) * | 2012-10-26 | 2016-06-14 | Korea Atomic Energy Research Institute | N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient |
CN105849568B (zh) * | 2013-11-14 | 2018-05-04 | 恩多塞特公司 | 用于正电子发射断层术的化合物 |
WO2016089879A1 (en) * | 2014-12-01 | 2016-06-09 | Endocyte, Inc. | Conjugates of garftase inhibitors |
WO2016168471A1 (en) * | 2015-04-17 | 2016-10-20 | Endocyte, Inc. | Dual disulfide drug conjugates |
CN112142739A (zh) * | 2020-10-21 | 2020-12-29 | 上海交通大学医学院附属仁济医院 | 靶向叶酸受体的放射性叶酸衍生物及其制备方法和应用 |
-
2022
- 2022-04-13 MX MX2023012114A patent/MX2023012114A/es unknown
- 2022-04-13 CA CA3214074A patent/CA3214074A1/en active Pending
- 2022-04-13 JP JP2023562839A patent/JP2024516797A/ja active Pending
- 2022-04-13 IL IL307499A patent/IL307499A/en unknown
- 2022-04-13 BR BR112023021189A patent/BR112023021189A2/pt unknown
- 2022-04-13 AU AU2022257363A patent/AU2022257363A1/en active Pending
- 2022-04-13 TW TW111114129A patent/TW202304518A/zh unknown
- 2022-04-13 AR ARP220100955A patent/AR125353A1/es unknown
- 2022-04-13 KR KR1020237038838A patent/KR20230171964A/ko unknown
- 2022-04-13 EP EP22718302.7A patent/EP4323017A1/en active Pending
- 2022-04-13 WO PCT/IB2022/053493 patent/WO2022219569A1/en active Application Filing
- 2022-04-13 CN CN202280023467.0A patent/CN117083088A/zh active Pending
-
2023
- 2023-10-12 CO CONC2023/0013494A patent/CO2023013494A2/es unknown
- 2023-10-12 CL CL2023003063A patent/CL2023003063A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202304518A (zh) | 2023-02-01 |
CL2023003063A1 (es) | 2024-05-03 |
JP2024516797A (ja) | 2024-04-17 |
CN117083088A (zh) | 2023-11-17 |
KR20230171964A (ko) | 2023-12-21 |
BR112023021189A2 (pt) | 2024-02-06 |
CA3214074A1 (en) | 2022-10-20 |
WO2022219569A1 (en) | 2022-10-20 |
IL307499A (en) | 2023-12-01 |
EP4323017A1 (en) | 2024-02-21 |
MX2023012114A (es) | 2023-10-24 |
AU2022257363A1 (en) | 2023-10-12 |
CO2023013494A2 (es) | 2023-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105407889B (zh) | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 | |
BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
TW200614992A (en) | Combinations for the treatment of diseases involving cell proliferation | |
RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
RU2013121799A (ru) | Набор для претаргетинга, способ и агенты, применяемые в нем | |
AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
BR122013028012B8 (pt) | composto de ciclopentano de pirimidila hidroxilado e metoxilado, sua composição farmacêutica e seu método de preparação | |
RU2018122864A (ru) | Ингибиторы протеинкиназ, их способ получения и медицинское применение | |
AR047992A1 (es) | Diaminopirimidinas como antagonistas de p2x3 y p2x2/3 | |
AR046639A1 (es) | Combinaciones terapeuticas de anticuerpo anti- igfr1 | |
ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
BRPI0517917A (pt) | compostos, sais de adição de ácido, método para preparar os compostos, uso de compostos, composição topicamente aplicável, e, método para o tratamento de rugas de expressão e/ou relacionadas com a idade em pele humana | |
RU2013133813A (ru) | Средства для выведения биомолекул из кровотока | |
AU2016302243A1 (en) | Beta-substituted Beta-amino acids and analogs as chemotherapeutic agents and uses thereof | |
RU2014111079A (ru) | Композиции и способы для лечения нейродегенеративного заболевания | |
BRPI0510719A (pt) | derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos | |
EP3749653A1 (en) | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | |
CN113474014A (zh) | 放射性免疫缀合物与dna损伤和修复抑制剂组合疗法 | |
HRP20090629T1 (hr) | Aminoacil-prolijek derivati i lijekovi za liječenje tromboemboličkih poremećaja | |
AR125209A1 (es) | Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares | |
BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
RU2007101515A (ru) | Совершенствованные конъюгаты n4 хелатообразующих агентов | |
MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
AR125353A1 (es) | Agentes radioterapéuticos dirigidos al receptor de folato y su uso | |
JP2019123731A5 (es) |